Patient-level costs of staged unilateral versus immediate bilateral symmetrization mammoplasty in breast-conserving surgery

Grant, Yasmin, Thiruchelvam, Paul T.R., Kovacevic, Lana, Mossialos, Elias ORCID: 0000-0001-8664-9297, Al-Mufti, Ragheed, Hogben, Katy, Hadjiminas, Dimitri J. and Leff, Daniel R. (2022) Patient-level costs of staged unilateral versus immediate bilateral symmetrization mammoplasty in breast-conserving surgery. BJS open, 6 (3). ISSN 2474-9842

Text (zrac073) - Published Version Available under License Creative Commons Attribution. Download (360kB)

• Author

Abstract

BACKGROUND: Following therapeutic mammoplasty (TM), the contralateral breast may require a later balancing procedure to optimize shape and symmetry. The alternative is to offer patients simultaneous TM with immediate contralateral symmetrization via a dual-surgeon approach, with the goal of reducing costs and minimizing the number of subsequent hospital appointments in an era of COVID-19 surges. The aim of this cost-consequence analysis is to characterize the cost-benefit of immediate bilateral symmetrization dual-operator mammoplasty versus staged unilateral single operator for breast cancer surgery. METHOD: A prospective single-centre observational study was conducted at an academic teaching centre for breast cancer surgery in the UK. Pseudonymized data for clinicopathological variables and procedural care information, including the type of initial breast-conserving surgery and subsequent reoperation(s), were extracted from the electronic patient record. Financial data were retrieved using the Patient-Level Information and Costing Systems. RESULTS: Between April 2014 and March 2020, 232 women received either immediate bilateral (n = 44), staged unilateral (n = 57) for breast cancer, or unilateral mammoplasty alone (n = 131). The median (interquartile range (i.q.r.)) additional cost of unilateral mammoplasty with staged versus immediate bilateral mammoplasty was €5500 (€4330 to €6570) per patient (P < 0.001), which represents a total supplementary financial burden of €313 462 to the study institution. There was no significant difference between groups in age, Charlson comorbidity index, operating minutes, time to adjuvant radiotherapy in months, or duration of hospital stay. CONCLUSION: Synchronous dual-surgeon immediate bilateral TM can deliver safe immediate symmetrization and is financially beneficial, without delay to receipt of adjuvant therapy, or additional postoperative morbidity.

Item Type:	Article
Official URL:	https://academic.oup.com/bjsopen
Additional Information:	© 2022 The Authors
Divisions:	LSE Health Health Policy
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited:	18 Jul 2022 10:36
Last Modified:	12 Dec 2024 03:08
URI:	http://eprints.lse.ac.uk/id/eprint/115589

Actions (login required)

View Item